

Paola Ciceri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11368166/publications.pdf>

Version: 2024-02-01

47
papers

1,224
citations

471509
17
h-index

377865
34
g-index

48
all docs

48
docs citations

48
times ranked

1536
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular disease in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, iii28-iii34.	0.7	320
2	The Key Role of Phosphate on Vascular Calcification. <i>Toxins</i> , 2019, 11, 213.	3.4	99
3	Production of leukotrienes in a model of focal cerebral ischaemia in the rat. <i>British Journal of Pharmacology</i> , 2001, 133, 1323-1329.	5.4	98
4	Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. <i>Journal of Nephrology</i> , 2017, 30, 677-687.	2.0	56
5	Vitamin K in Chronic Kidney Disease. <i>Nutrients</i> , 2019, 11, 168.	4.1	54
6	The Cardiovascular Burden in End-Stage Renal Disease. <i>Contributions To Nephrology</i> , 2017, 191, 44-57.	1.1	51
7	Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis. <i>Atherosclerosis</i> , 2016, 254, 93-101.	0.8	48
8	Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 122-127.	0.7	46
9	Effects of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 382-389.	2.9	38
10	Pathophysiology of Calcium and Phosphate Metabolism Impairment in Chronic Kidney Disease. <i>Blood Purification</i> , 2009, 27, 338-344.	1.8	37
11	The Role of Vitamin K in Vascular Calcification. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 437-444.	1.4	33
12	Osteonectin (SPARC) Expression in Vascular Calcification: In Vitro and Ex Vivo Studies. <i>Calcified Tissue International</i> , 2016, 99, 472-480.	3.1	27
13	COVID-19 pandemic era: is it time to promote home dialysis and peritoneal dialysis?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, i6-i13.	2.9	25
14	A new in vitro model to delay high phosphate-induced vascular calcification progression. <i>Molecular and Cellular Biochemistry</i> , 2015, 410, 197-206.	3.1	23
15	High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs. <i>International Journal of Cardiology</i> , 2019, 297, 94-103.	1.7	23
16	Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5925.	4.1	22
17	The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification. <i>Biochemical and Biophysical Research Communications</i> , 2012, 418, 770-773.	2.1	18
18	Lanthanum Prevents High Phosphate-Induced Vascular Calcification by Preserving Vascular Smooth Muscle Lineage Markers. <i>Calcified Tissue International</i> , 2013, 92, 521-530.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Nutritional vitamin D in CKD: Should we measure? Should we treat?. Clinica Chimica Acta, 2020, 501, 186-197.	1.1	16
20	Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease. Expert Review of Clinical Pharmacology, 2017, 10, 1073-1084.	3.1	14
21	COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. Blood Purification, 2021, 50, 740-749.	1.8	14
22	The Calcimimetic Calindol Prevents High Phosphate-Induced Vascular Calcification by Upregulating Matrix GLA Protein. Nephron Experimental Nephrology, 2013, 122, 75-82.	2.2	13
23	Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease. Annals of Translational Medicine, 2019, 7, 55-55.	1.7	13
24	Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins. Toxins, 2021, 13, 380.	3.4	13
25	Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly. Drugs and Aging, 2019, 36, 885-895.	2.7	11
26	Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients, 2020, 12, 1609.	4.1	11
27	Uremic Patients with Increased Vascular Calcification Score Have Serum with High Calcific Potential: Role of Vascular Smooth Muscle Cell Osteoblastic Differentiation and Apoptosis. Blood Purification, 2019, 48, 142-149.	1.8	10
28	The emerging role of iron in heart failure and vascular calcification in CKD. CKJ: Clinical Kidney Journal, 2021, 14, 739-745.	2.9	9
29	The role of activin: the other side of chronic kidney diseaseâ€“mineral bone disorder?. Nephrology Dialysis Transplantation, 2021, 36, 966-974.	0.7	9
30	Cardiovascular calcifications in kidney transplant recipients. Nephrology Dialysis Transplantation, 2022, 37, 2063-2071.	0.7	9
31	Phosphate Control in Peritoneal Dialysis. Contributions To Nephrology, 2012, 178, 116-123.	1.1	8
32	Restoring the Physiology of Vitamin D Receptor Activation and the Concept of Selectivity. Contributions To Nephrology, 2011, 171, 151-156.	1.1	6
33	Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons?. Blood Purification, 2016, 42, 44-48.	1.8	6
34	Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study. CKJ: Clinical Kidney Journal, 2021, 14, 1798-1807.	2.9	5
35	Ectopic Calcification in Uremia: Where Do We Stand?. Blood Purification, 2020, 49, 641-642.	1.8	4
36	Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency. Expert Opinion on Drug Safety, 2021, 20, 1333-1349.	2.4	4

#	ARTICLE	IF	CITATIONS
37	A roadmap to parathyroidectomy for kidney transplant candidates. CKJ: Clinical Kidney Journal, 2022, 15, 1459-1474.	2.9	4
38	1,25-dihydroxyvitamin D as Predictor of Renal Worsening Function in Chronic Kidney Disease. Results From the PASCAL-1,25D Study. Frontiers in Medicine, 2022, 9, 840801.	2.6	4
39	Calciphylaxis after kidney transplantation: a rare but life-threatening disorder. CKJ: Clinical Kidney Journal, 2022, 15, 611-614.	2.9	2
40	The Role of Uremic Retention Solutes in the MIA Syndrome in Hemodialysis Subjects. Blood Purification, 2023, 52, 41-53.	1.8	2
41	Serum PTH levels in dialysis: better safe than sorry. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882097417.	3.2	1
42	Phosphate binders in dialysis: better satisfied than sorry. CKJ: Clinical Kidney Journal, 2021, 14, 1859-1860.	2.9	1
43	Do we need new phosphate binders in dialysis?. CKJ: Clinical Kidney Journal, 2021, 14, 474-475.	2.9	1
44	Vitamin D receptor activation and prevention of arterial aging. , 2020, , 409-425.		0
45	P1392ANALYSIS OF CALCIFYING POTENTIAL OF UREMIC SERUM FROM HAEMODIALYSIS PATIENTS TREATED WITH A MEDIUM CUT-OFF (THERANOVA) DIALYSER: A PROSPECTIVE, CROSS-OVER STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
46	Transforming the frail and elderly patient into an Iron Man: how to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease. Journal of Nephrology, 2021, 34, 1049-1051.	2.0	0
47	An update on tenapanor to treat hyperphosphatemia. Drugs of Today, 2022, 58, 33-53.	1.1	0